# US 2019/0239937 A1 · Augmentation of Abscopal Effect of Cryotherapy and other Tumor Cell Death by Anti-angiogenic and Anti-tumor Vaccination

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0239937 A1
- Document ID: US20190239937A1
- Status: Published application
- Kind: A1
- Application number: 16/266,499
- Filed: 2019-02-04
- Published: 2019-08-08
- Earliest claimed: 2018-02-02
- Assignees: Batu Biologics, Inc.
- Applicants: Batu Biologics, Inc.
- Inventors: Samuel C. Wagner; Thomas E. Ichim
- Web page: https://patentgrep.com/patent/US20190239937A1

## CPC

- A61B 18/02: by cooling, e.g. cryogenic techniques
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/428: {Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}
- A61P 35/00: Antineoplastic agents
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2039/51: {comprising whole cells, viruses or DNA/RNA}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are means, methods, and compositions, useful for augmenting immune response to tumor cell death occurring in the body, wherein the tumor cell death acts as a source of antigens to stimulate an anti-cancer immune response. In one embodiment of the invention cryosurgery is performed in a manner to facilitate immune mediated killing of distant tumors, in effect causing an abscopal reaction, the amplification of the abscopal reaction is performed by preimmunization with antigen compositions generated to target tumor endothelium. In another embodiment the invention teaches the amplification of abscopal effect by preimmunizing with placental and/or tumor antigens prior to induction of necrotic cell death through means such as cryoablation, hyperthermia, radiation therapy, radiation therapy and intravenous vitamin C, and chemotherapy.

## Claims

### Claim 1

A method of increasing systemic antitumor effects of the immune system in a patient suffering from cancer comprising:
inducing tumor cell death in an immunogenic manner; and
administering at least one capable of stimulating an immune response which inhibiting/destroying tumor endothelial cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the at least one agent capable of stimulating an immune response that inhibits/destroys tumor endothelial cells prior to induction of immunogenic cell death.

### Claim 3 (depends on 1)

The method of claim 1, wherein the immunogenic cell death is necrosis.

### Claim 4 (depends on 1)

The method of claim 1, wherein the immunogenic cell death is associated with release of mitochondria into the extracellular space.

### Claim 5 (depends on 1)

The method of claim 1, wherein the immunogenic cell death is caused by at least one of cryosurgery, hyperthermia, localized irradiation, and chemotherapy.

### Claim 6 (depends on 1)

The method of claim 1, wherein immunogenicity of cell death is augmented by pretreatment of the tumor with agents capable of augmenting markers of immunogenicity.

### Claim 7 (depends on 6)

The method of claim 6, wherein the agents capable of augmenting markers of immunogenicity are selected from a group consisting of histone deacetylase inhibitors, DNA methyltransferase inhibitors, interferon alpha, interferon gamma, and lipoic acid.

### Claim 8 (depends on 1)

The method of claim 1, wherein immunogenicity of cell death is accomplished by administration of dendritic cells prior to induction of immunogenic tumor cell death.

### Claim 9 (depends on 1)

The method of claim 1, wherein the agent capable of inducing immune response towards tumor endothelial cells is an endothelial cell vaccine, wherein the endothelial cells are generated in a manner to resemble tumor endothelium.

### Claim 10 (depends on 9)

The method of claim 9, wherein the agent capable of inducing immune response towards tumor endothelial cells possesses an antigenic moiety resembling proteins selected from a group consisting of ROBO 1-8, EGF-R, TEM-3, and CD105.

### Claim 11 (depends on 9)

The method of claim 9, wherein the agent capable of inducing immune response towards tumor endothelial cells is derived from placental endothelial cells.

### Claim 12 (depends on 11)

The method of claim 11, wherein the endothelial cells are cultured under at least one hypoxia and acidic conditions.

### Claim 13 (depends on 11)

The method of claim 11, wherein the endothelial cells are cultured with interferon gamma to augment expression of HLA antigens.

### Claim 14 (depends on 11)

The method of claim 11, wherein the endothelial cells are endothelial progenitor cells.

### Claim 15 (depends on 11)

The method of claim 11, wherein the endothelial cells are allogeneic to the recipient.

### Claim 16 (depends on 11)

The method of claim 11, wherein the endothelial cells are xenogeneic to the recipient.

### Claim 17 (depends on 1)

The method of claim 1, wherein induction of immunity towards tumor endothelium is accomplished by immunization with ValloVax.

### Claim 18 (depends on 1)

The method of claim 1, wherein induction of antibody responses is provoked towards tumor endothelium prior to induction of immunogenic cell death in order to enhance immunogenicity of the immunogenic cell death.

### Claim 19 (depends on 1)

The method of claim 1, wherein immunity to tumor antigens is induced prior to induction of immunogenic cancer cell death.

### Claim 20 (depends on 19)

The method of claim 19, wherein the immunity is induced by vaccination with immunization means selected from whole cell vaccines, peptide vaccine, c) mRNA vaccine, dendritic cell vaccine, and protein vaccine.
